Tendinitis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Tendinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tendinitis: Overview
Tendinitis is an inflammation of a tendon, a group of sturdy fibers that connects a muscle to the nearby bone. Another commonly used term for tendinitis is tendinopathy. Tendinitis is generally caused by injury, trauma, or overuse of a joint. Tendinitis may be referred to by a more specific description depending on the location where it occurs, such as Achilles tendinitis or tennis elbow. The elbows, heel, shoulder and wrist are common locations for tendinitis. Tendinitis is treated with rest along with medications to relieve pain and reduce inflammation. Physical therapy can be helpful to improve muscle strength and enhance healing. In some cases, surgery will need to be performed to repair tendon damage.
'Tendinitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinitis pipeline landscape is provided which includes the disease overview and Tendinitis treatment guidelines. The assessment part of the report embraces, in depth Tendinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Tendinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tendinitis Emerging Drugs
Further product details are provided in the report
Tendinitis: Therapeutic Assessment
This segment of the report provides insights about the different Tendinitis drugs segregated based on following parameters that define the scope of the report, such as:
Tendinitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinitis drugs.
Tendinitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Tendinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tendinitis: Overview
Tendinitis is an inflammation of a tendon, a group of sturdy fibers that connects a muscle to the nearby bone. Another commonly used term for tendinitis is tendinopathy. Tendinitis is generally caused by injury, trauma, or overuse of a joint. Tendinitis may be referred to by a more specific description depending on the location where it occurs, such as Achilles tendinitis or tennis elbow. The elbows, heel, shoulder and wrist are common locations for tendinitis. Tendinitis is treated with rest along with medications to relieve pain and reduce inflammation. Physical therapy can be helpful to improve muscle strength and enhance healing. In some cases, surgery will need to be performed to repair tendon damage.
'Tendinitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinitis pipeline landscape is provided which includes the disease overview and Tendinitis treatment guidelines. The assessment part of the report embraces, in depth Tendinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tendinitis R&D. The therapies under development are focused on novel approaches to treat/improve Tendinitis.
This segment of the Tendinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tendinitis Emerging Drugs
- SI-613: Seikagaku Corporation
- MP1032: MetrioPharm
Further product details are provided in the report
Tendinitis: Therapeutic Assessment
This segment of the report provides insights about the different Tendinitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tendinitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Tendinitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinitis drugs.
Tendinitis Report Insights
- Tendinitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tendinitis drugs?
- How many Tendinitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tendinitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tendinitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Seikagaku Corporation
- MetrioPharm
- MiMedx
- Zhejiang Xingyue Biotechnology Co., Ltd.
- R3 Stem Cell
- Dobecure
- Causeway Therapeutics
- SI-613
- MP 1032
- dHACM
- Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection
- CWT 001
Introduction
Executive Summary
Tendinitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tendinitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tendinitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tendinitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
dHACM: MiMedx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
MP 1032: MetrioPharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Tendinitis Key Companies
Tendinitis Key Products
Tendinitis- Unmet Needs
Tendinitis- Market Drivers and Barriers
Tendinitis- Future Perspectives and Conclusion
Tendinitis Analyst Views
Tendinitis Key Companies
Appendix
Executive Summary
Tendinitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tendinitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tendinitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tendinitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
dHACM: MiMedx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
MP 1032: MetrioPharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Tendinitis Key Companies
Tendinitis Key Products
Tendinitis- Unmet Needs
Tendinitis- Market Drivers and Barriers
Tendinitis- Future Perspectives and Conclusion
Tendinitis Analyst Views
Tendinitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Tendinitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Tendinitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Tendinitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Tendinitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
